NCT04843579View on ClinicalTrials.gov

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

December 30, 2022

Conditions
Myeloma MultipleMyelomaRefractory Multiple Myeloma
Interventions
DRUG

Selinexor

Given as 60 mg oral capsule

DRUG

Clarithromycin

Given as 500 mg oral capsule

DRUG

Pomalidomide

Given as 4 mg oral capsule

DRUG

Dexamethasone

Given as 40 mg oral capsule

Trial Locations (2)

10065

Weill Cornell Medicine - Multiple Myeloma Center, New York

11215

NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER